

Jubilant Prodel LLC
Balance Sheet as at 31 March 2026

		USD	USD
	Notes	As at 31 March 2026	As at 31 March 2025
ASSETS			
Non-current assets			
Intangible assets under development	3	7,602,332	7,565,968
Total non-current assets		7,602,332	7,565,968
Current assets			
Financial assets			
i. Cash and cash equivalents	4	1,529	381
Other current assets	5	220	220
Total current assets		1,749	601
Total assets		7,604,081	7,566,568
EQUITY AND LIABILITIES			
Equity			
Equity share capital	6	7,819,317	7,786,317
Other equity		(314,428)	(310,785)
Total Equity		7,504,889	7,475,531
LIABILITIES			
Current liabilities			
Financial liabilities			
i. Trade payables	7	99,192	91,037
Total current liabilities		99,192	91,037
Total liabilities		99,192	91,037
Total equity and liabilities		7,604,081	7,566,567



Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026



Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Prodel LLC
Statement of Profit and Loss for the year ended 31 March 2026

		USD	USD
	Notes	For the year ended 31 March 2026	For the year ended 31 March 2025
Other Income	8	433	464
Total income		433	464
Expenses			
Other expenses	9	4,076	3,474
Total expenses		4,076	3,474
(Loss)/ profit before tax		(3,643)	(3,010)
Tax expense			
- Current tax		-	-
- Deferred tax		-	-
Total tax expense		-	-
(Loss)/ profit for the year		(3,643)	(3,010)
Other comprehensive income			
Items that will be reclassified to profit or loss			
Exchange differences on translation of foreign operations		-	-
Other comprehensive income for the year, net of tax		-	-
Total comprehensive (loss)/ income/(loss) for the year		(3,643)	(3,010)



Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026



Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Prodel LLC
Statement of changes in equity for the year ended 31 March 2026

A) Equity share capital

	USD
Balance as at 1 April 2024	7,751,317
Additions during the year	35,000
Balance as at 31 March 2025	7,786,317
Additions during the year	33,000
Balance as at 31 March 2026	7,819,317

B) Other equity

	USD	
	Reserves and Surplus	
	Retained earnings	Total
Balance as at 1 April 2024	307,775	307,775
Total comprehensive loss for the year	3,010	3,010
Balances as at 31 March 2025	310,785	310,785
Total comprehensive loss for the year	3,643	3,643
Balances as at 31 March 2026	314,428	314,428



Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026



Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Prodel LLC
Statement of Cash Flows for the year ended 31 March 2026

	USD	USD
	For the year ended 31 March 2026	For the year ended 31 March 2025
A. Cash flow from operating activities		
Profit/(Loss) before tax	(3,643)	(3,010)
Operating cash flow before working capital changes	(3,643)	(3,010)
Decrease/(Increase) in trade and other receivables	-	1,519
Increase/ (Decrease) in trade payables, provisions and other liabilities	8,155	8,599
Cash generated from/(used in) operations	4,512	7,108
Income tax and wealth tax paid (net of refund)	-	-
Net cash generated from/(used in) operating activities	4,512	7,108
B. Cash flow from investing activities		
Purchase of intangible assets (including capital work-in-progress and intangible asset under development)	(36,364)	(45,687)
Net cash used in investing activities	(36,364)	(45,687)
C. Cash flow arising from financing activities		
Proceeds from issuance of equity	33,000	35,000
Net cash generated from financing activities	33,000	35,000
D. Effect of exchange rate changes		-
Net (decrease)/increase in cash and cash equivalents (A+B+C+D)	1,147	(3,579)
Add: cash and cash equivalents at the beginning of year	380	3,959
Cash and cash equivalents at the end of the year	1,527	380



Shyam Pattabiraman
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026



Anuj Mohnot
Director

Place: Yardley, Pennsylvania
Date: 18 May 2026

Jubilant Prodel LLC
Notes to the financial statements for the year ended 31 March 2026

1. Corporate information

Jubilant Prodel LLC. ("the Company") was incorporated in United States of America under the local laws of Delaware on 19 February 2019. The Company is a fully owned subsidiary of Jubilant Therapeutics India Limited. The Company will focus on the discovery and development of novel drugs for the treatment of cancer in the area of Oncology and Auto-Immune

2. Significant accounting policies

This note provides a list of the significant accounting policies adopted in the preparation of these Standalone Financial Statements ("standalone financial statements").

(a) Basis of preparation

(i) Statement of compliance

These standalone financial statements have been prepared solely for the purpose of submission of Annual Performance Report to the Reserve Bank of India, in accordance with Indian Accounting Standards (Ind AS) issued by the Institute of Chartered Accountants of India (ICAI).

(ii) Historical cost convention

The Standalone financial statements have been prepared under historical cost convention on accrual basis, unless otherwise stated.

(b) Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (i.e. the "functional currency"). The functional currency of the Company is U.S. Dollars ("USD"). These financial statements are presented in USD

(c) Current versus non-current classification

The Company presents assets and liabilities in the Standalone Balance Sheet based on current/ non-current classification.

An asset is treated as current when:

- It is expected to be realized or intended to be sold or consumed in normal operating cycle;
- It is held primarily for the purpose of trading;
- It is expected to be realized within twelve months after the reporting period; or
- It is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

Current assets include the current portion of non-current financial assets.

The Company classifies all other assets as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle;
 - It is held primarily for the purpose of trading;
- Place: New Jersey
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

The Company classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities respectively.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified period less than twelve months as its operating cycle for the purpose of current/non-current classification of assets and liabilities.

Note 3: Intangible assets under development

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Intangible assets under development	7,602,332	7,565,968
Total Intangible assets under development	7,602,332	7,565,968

Note 4: Cash and cash equivalents

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Balances with banks		
In current accounts	1,529	381
Total cash and cash equivalents	1,529	381

Note 5: Other current assets

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Prepaid expenses	220	220
	220	220

Note 6: Equity share Capital

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Issued, subscribed and paid up		
Equity shares	7,819,317	7,786,317

- 1) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.
2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.
3) The details of shareholders holding more than 5% shares in the Company:

	As at		As at	
	31 March 2026		31 March 2025	
	No of units	% holding in the class	No of units	% holding in the class
Name of the Shareholder				
Jubilant Therapeutics Inc	100	100%	100	100%

4) The reconciliation of the number of shares outstanding as at beginning and at end of the reporting period

	As at		As at	
	31 March 2026		31 March 2025	
	No of units	USD	No of units	USD
Numbers of units at the beginning of the year	100	7,786,317	100	7,751,317
Add: Units issued during the year		33,000	-	35,000
Number of units at the end of the year	100	7,819,317	100	7,786,317

5) Equity shares held by holding company/ultimate holding company is set out below:

Particulars	As at	As at
	31 March 2026	31 March 2025
	No of units	No of units
Jubilant Therapeutics Inc	100	100

Note 7: Trade payables

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Trade payables	15,670	7,482
Due to related parties	83,523	83,555
Total trade payables	99,192	91,037

Jubilant Prodel LLC**Notes to the financial statements for the year ended 31 March 2026****Note 8: Other Income**

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Interest Income	220	402
Exchange (Gain)/ Loss	213	62
Total other expenses	433	464

Note 9: Other expenses

	USD	USD
	As at	As at
	31 March 2026	31 March 2025
Bank charges	4,076	3,474
Total other expenses	4,076	3,474